15
Participants
Start Date
February 28, 2013
Primary Completion Date
October 31, 2014
Study Completion Date
October 31, 2014
beta3-adrenergic receptor agonist
single dose. The subjects were randomized to receive placebo on one study day and active beta3-adrenergic receptor agonist on the other study day.
Beth Israel Deaconess Medical Center, Boston
National Institutes of Health (NIH)
NIH
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Aaron Cypess
OTHER